nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—TNF—Alzheimer's disease	0.215	0.434	CbGaD
Thalidomide—PTGS1—Alzheimer's disease	0.179	0.36	CbGaD
Thalidomide—PTGS2—Alzheimer's disease	0.102	0.206	CbGaD
Thalidomide—CYP2C19—Memantine—Alzheimer's disease	0.0485	0.51	CbGbCtD
Thalidomide—CYP2C9—Donepezil—Alzheimer's disease	0.0465	0.489	CbGbCtD
Thalidomide—NFKB1—forebrain—Alzheimer's disease	0.00221	0.0629	CbGeAlD
Thalidomide—CRBN—embryo—Alzheimer's disease	0.0021	0.0596	CbGeAlD
Thalidomide—NFKB1—telencephalon—Alzheimer's disease	0.00203	0.0579	CbGeAlD
Thalidomide—FGFR2—embryo—Alzheimer's disease	0.00188	0.0534	CbGeAlD
Thalidomide—CRBN—forebrain—Alzheimer's disease	0.00185	0.0527	CbGeAlD
Thalidomide—CRBN—telencephalon—Alzheimer's disease	0.0017	0.0485	CbGeAlD
Thalidomide—FGFR2—forebrain—Alzheimer's disease	0.00166	0.0473	CbGeAlD
Thalidomide—FGFR2—telencephalon—Alzheimer's disease	0.00153	0.0435	CbGeAlD
Thalidomide—NFKB1—nervous system—Alzheimer's disease	0.0012	0.0342	CbGeAlD
Thalidomide—NFKB1—central nervous system—Alzheimer's disease	0.00116	0.0329	CbGeAlD
Thalidomide—NFKB1—cerebellum—Alzheimer's disease	0.00113	0.0321	CbGeAlD
Thalidomide—Pomalidomide—TNF—Alzheimer's disease	0.00112	0.233	CrCbGaD
Thalidomide—Menadione—F2—Alzheimer's disease	0.00102	0.211	CrCbGaD
Thalidomide—CRBN—nervous system—Alzheimer's disease	0.00101	0.0286	CbGeAlD
Thalidomide—PTGS1—blood vessel—Alzheimer's disease	0.001	0.0285	CbGeAlD
Thalidomide—CRBN—central nervous system—Alzheimer's disease	0.000969	0.0276	CbGeAlD
Thalidomide—PTGS2—blood vessel—Alzheimer's disease	0.000956	0.0272	CbGeAlD
Thalidomide—CRBN—cerebellum—Alzheimer's disease	0.000947	0.0269	CbGeAlD
Thalidomide—NFKB1—brain—Alzheimer's disease	0.000917	0.0261	CbGeAlD
Thalidomide—Menadione—MAOB—Alzheimer's disease	0.000916	0.19	CrCbGaD
Thalidomide—FGFR2—nervous system—Alzheimer's disease	0.000901	0.0257	CbGeAlD
Thalidomide—FGFR2—central nervous system—Alzheimer's disease	0.000868	0.0247	CbGeAlD
Thalidomide—FGFR2—cerebellum—Alzheimer's disease	0.000848	0.0241	CbGeAlD
Thalidomide—CRBN—brain—Alzheimer's disease	0.000769	0.0219	CbGeAlD
Thalidomide—FGFR2—brain—Alzheimer's disease	0.000689	0.0196	CbGeAlD
Thalidomide—Menadione—MTHFR—Alzheimer's disease	0.000652	0.135	CrCbGaD
Thalidomide—Lenalidomide—PTGS2—Alzheimer's disease	0.000573	0.119	CrCbGaD
Thalidomide—PTGS2—embryo—Alzheimer's disease	0.000571	0.0162	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—Alzheimer's disease	0.000532	0.111	CrCbGaD
Thalidomide—PTGS1—forebrain—Alzheimer's disease	0.000528	0.015	CbGeAlD
Thalidomide—PTGS2—forebrain—Alzheimer's disease	0.000505	0.0144	CbGeAlD
Thalidomide—CYP2E1—telencephalon—Alzheimer's disease	0.000504	0.0143	CbGeAlD
Thalidomide—PTGS1—telencephalon—Alzheimer's disease	0.000485	0.0138	CbGeAlD
Thalidomide—PTGS2—telencephalon—Alzheimer's disease	0.000464	0.0132	CbGeAlD
Thalidomide—CYP1A1—nervous system—Alzheimer's disease	0.000326	0.00928	CbGeAlD
Thalidomide—CYP1A1—central nervous system—Alzheimer's disease	0.000314	0.00894	CbGeAlD
Thalidomide—CYP2E1—nervous system—Alzheimer's disease	0.000297	0.00847	CbGeAlD
Thalidomide—PTGS1—nervous system—Alzheimer's disease	0.000287	0.00816	CbGeAlD
Thalidomide—CYP2E1—central nervous system—Alzheimer's disease	0.000286	0.00815	CbGeAlD
Thalidomide—CYP2E1—cerebellum—Alzheimer's disease	0.00028	0.00797	CbGeAlD
Thalidomide—PTGS1—central nervous system—Alzheimer's disease	0.000276	0.00785	CbGeAlD
Thalidomide—PTGS2—nervous system—Alzheimer's disease	0.000274	0.0078	CbGeAlD
Thalidomide—PTGS2—central nervous system—Alzheimer's disease	0.000264	0.00751	CbGeAlD
Thalidomide—PTGS2—cerebellum—Alzheimer's disease	0.000258	0.00734	CbGeAlD
Thalidomide—CYP1A1—brain—Alzheimer's disease	0.000249	0.0071	CbGeAlD
Thalidomide—CYP2E1—brain—Alzheimer's disease	0.000227	0.00647	CbGeAlD
Thalidomide—PTGS1—brain—Alzheimer's disease	0.000219	0.00623	CbGeAlD
Thalidomide—PTGS2—brain—Alzheimer's disease	0.000209	0.00596	CbGeAlD
Thalidomide—Urinary tract disorder—Memantine—Alzheimer's disease	0.00018	0.000819	CcSEcCtD
Thalidomide—Tachycardia—Galantamine—Alzheimer's disease	0.00018	0.000818	CcSEcCtD
Thalidomide—Oedema peripheral—Memantine—Alzheimer's disease	0.00018	0.000817	CcSEcCtD
Thalidomide—Arrhythmia—Donepezil—Alzheimer's disease	0.000179	0.000816	CcSEcCtD
Thalidomide—Rhinitis—Rivastigmine—Alzheimer's disease	0.000179	0.000814	CcSEcCtD
Thalidomide—Skin disorder—Galantamine—Alzheimer's disease	0.000179	0.000814	CcSEcCtD
Thalidomide—Urethral disorder—Memantine—Alzheimer's disease	0.000179	0.000813	CcSEcCtD
Thalidomide—Hepatitis—Rivastigmine—Alzheimer's disease	0.000178	0.000812	CcSEcCtD
Thalidomide—Hyperhidrosis—Galantamine—Alzheimer's disease	0.000178	0.00081	CcSEcCtD
Thalidomide—Hypoaesthesia—Rivastigmine—Alzheimer's disease	0.000177	0.000808	CcSEcCtD
Thalidomide—Alopecia—Donepezil—Alzheimer's disease	0.000177	0.000807	CcSEcCtD
Thalidomide—Pharyngitis—Rivastigmine—Alzheimer's disease	0.000177	0.000806	CcSEcCtD
Thalidomide—Urinary tract disorder—Rivastigmine—Alzheimer's disease	0.000176	0.000802	CcSEcCtD
Thalidomide—Mental disorder—Donepezil—Alzheimer's disease	0.000176	0.000801	CcSEcCtD
Thalidomide—Oedema peripheral—Rivastigmine—Alzheimer's disease	0.000176	0.0008	CcSEcCtD
Thalidomide—Visual impairment—Memantine—Alzheimer's disease	0.000176	0.0008	CcSEcCtD
Thalidomide—Anorexia—Galantamine—Alzheimer's disease	0.000175	0.000798	CcSEcCtD
Thalidomide—Urethral disorder—Rivastigmine—Alzheimer's disease	0.000175	0.000796	CcSEcCtD
Thalidomide—Malnutrition—Donepezil—Alzheimer's disease	0.000175	0.000795	CcSEcCtD
Thalidomide—Erythema multiforme—Memantine—Alzheimer's disease	0.000172	0.000784	CcSEcCtD
Thalidomide—Flatulence—Donepezil—Alzheimer's disease	0.000172	0.000784	CcSEcCtD
Thalidomide—Hypotension—Galantamine—Alzheimer's disease	0.000172	0.000783	CcSEcCtD
Thalidomide—Visual impairment—Rivastigmine—Alzheimer's disease	0.000172	0.000782	CcSEcCtD
Thalidomide—Tension—Donepezil—Alzheimer's disease	0.000171	0.000781	CcSEcCtD
Thalidomide—Dysgeusia—Donepezil—Alzheimer's disease	0.000171	0.000779	CcSEcCtD
Thalidomide—Eye disorder—Memantine—Alzheimer's disease	0.00017	0.000775	CcSEcCtD
Thalidomide—Tinnitus—Memantine—Alzheimer's disease	0.00017	0.000774	CcSEcCtD
Thalidomide—Nervousness—Donepezil—Alzheimer's disease	0.00017	0.000773	CcSEcCtD
Thalidomide—Cardiac disorder—Memantine—Alzheimer's disease	0.000169	0.00077	CcSEcCtD
Thalidomide—Back pain—Donepezil—Alzheimer's disease	0.000169	0.000769	CcSEcCtD
Thalidomide—Erythema multiforme—Rivastigmine—Alzheimer's disease	0.000169	0.000767	CcSEcCtD
Thalidomide—Muscle spasms—Donepezil—Alzheimer's disease	0.000168	0.000765	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Galantamine—Alzheimer's disease	0.000168	0.000763	CcSEcCtD
Thalidomide—Eye disorder—Rivastigmine—Alzheimer's disease	0.000167	0.000758	CcSEcCtD
Thalidomide—Insomnia—Galantamine—Alzheimer's disease	0.000166	0.000758	CcSEcCtD
Thalidomide—Tinnitus—Rivastigmine—Alzheimer's disease	0.000166	0.000757	CcSEcCtD
Thalidomide—Cardiac disorder—Rivastigmine—Alzheimer's disease	0.000165	0.000753	CcSEcCtD
Thalidomide—Angiopathy—Memantine—Alzheimer's disease	0.000165	0.000753	CcSEcCtD
Thalidomide—Paraesthesia—Galantamine—Alzheimer's disease	0.000165	0.000752	CcSEcCtD
Thalidomide—Vision blurred—Donepezil—Alzheimer's disease	0.000165	0.00075	CcSEcCtD
Thalidomide—Immune system disorder—Memantine—Alzheimer's disease	0.000165	0.000749	CcSEcCtD
Thalidomide—Mediastinal disorder—Memantine—Alzheimer's disease	0.000164	0.000748	CcSEcCtD
Thalidomide—Tremor—Donepezil—Alzheimer's disease	0.000164	0.000745	CcSEcCtD
Thalidomide—Somnolence—Galantamine—Alzheimer's disease	0.000164	0.000745	CcSEcCtD
Thalidomide—Chills—Memantine—Alzheimer's disease	0.000164	0.000744	CcSEcCtD
Thalidomide—Arrhythmia—Memantine—Alzheimer's disease	0.000163	0.000741	CcSEcCtD
Thalidomide—Ill-defined disorder—Donepezil—Alzheimer's disease	0.000162	0.000738	CcSEcCtD
Thalidomide—Dyspepsia—Galantamine—Alzheimer's disease	0.000162	0.000737	CcSEcCtD
Thalidomide—Angiopathy—Rivastigmine—Alzheimer's disease	0.000162	0.000736	CcSEcCtD
Thalidomide—Anaemia—Donepezil—Alzheimer's disease	0.000162	0.000735	CcSEcCtD
Thalidomide—Alopecia—Memantine—Alzheimer's disease	0.000161	0.000733	CcSEcCtD
Thalidomide—Mediastinal disorder—Rivastigmine—Alzheimer's disease	0.000161	0.000731	CcSEcCtD
Thalidomide—Agitation—Donepezil—Alzheimer's disease	0.000161	0.000731	CcSEcCtD
Thalidomide—Chills—Rivastigmine—Alzheimer's disease	0.00016	0.000728	CcSEcCtD
Thalidomide—Decreased appetite—Galantamine—Alzheimer's disease	0.00016	0.000728	CcSEcCtD
Thalidomide—Mental disorder—Memantine—Alzheimer's disease	0.00016	0.000727	CcSEcCtD
Thalidomide—Arrhythmia—Rivastigmine—Alzheimer's disease	0.000159	0.000725	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Galantamine—Alzheimer's disease	0.000159	0.000723	CcSEcCtD
Thalidomide—Malnutrition—Memantine—Alzheimer's disease	0.000159	0.000722	CcSEcCtD
Thalidomide—Fatigue—Galantamine—Alzheimer's disease	0.000159	0.000722	CcSEcCtD
Thalidomide—Malaise—Donepezil—Alzheimer's disease	0.000158	0.000717	CcSEcCtD
Thalidomide—Alopecia—Rivastigmine—Alzheimer's disease	0.000158	0.000717	CcSEcCtD
Thalidomide—Constipation—Galantamine—Alzheimer's disease	0.000157	0.000716	CcSEcCtD
Thalidomide—Vertigo—Donepezil—Alzheimer's disease	0.000157	0.000715	CcSEcCtD
Thalidomide—Syncope—Donepezil—Alzheimer's disease	0.000157	0.000713	CcSEcCtD
Thalidomide—Flatulence—Memantine—Alzheimer's disease	0.000156	0.000712	CcSEcCtD
Thalidomide—Mental disorder—Rivastigmine—Alzheimer's disease	0.000156	0.000711	CcSEcCtD
Thalidomide—Tension—Memantine—Alzheimer's disease	0.000156	0.000709	CcSEcCtD
Thalidomide—Dysgeusia—Memantine—Alzheimer's disease	0.000155	0.000707	CcSEcCtD
Thalidomide—Malnutrition—Rivastigmine—Alzheimer's disease	0.000155	0.000707	CcSEcCtD
Thalidomide—Nervousness—Memantine—Alzheimer's disease	0.000154	0.000701	CcSEcCtD
Thalidomide—Loss of consciousness—Donepezil—Alzheimer's disease	0.000154	0.000699	CcSEcCtD
Thalidomide—Back pain—Memantine—Alzheimer's disease	0.000153	0.000699	CcSEcCtD
Thalidomide—Flatulence—Rivastigmine—Alzheimer's disease	0.000153	0.000696	CcSEcCtD
Thalidomide—Cough—Donepezil—Alzheimer's disease	0.000152	0.000694	CcSEcCtD
Thalidomide—Tension—Rivastigmine—Alzheimer's disease	0.000152	0.000693	CcSEcCtD
Thalidomide—Dysgeusia—Rivastigmine—Alzheimer's disease	0.000152	0.000692	CcSEcCtD
Thalidomide—Feeling abnormal—Galantamine—Alzheimer's disease	0.000152	0.00069	CcSEcCtD
Thalidomide—Convulsion—Donepezil—Alzheimer's disease	0.000151	0.000689	CcSEcCtD
Thalidomide—Hypertension—Donepezil—Alzheimer's disease	0.000151	0.000687	CcSEcCtD
Thalidomide—Nervousness—Rivastigmine—Alzheimer's disease	0.000151	0.000686	CcSEcCtD
Thalidomide—Gastrointestinal pain—Galantamine—Alzheimer's disease	0.00015	0.000685	CcSEcCtD
Thalidomide—Back pain—Rivastigmine—Alzheimer's disease	0.00015	0.000683	CcSEcCtD
Thalidomide—Vision blurred—Memantine—Alzheimer's disease	0.00015	0.000681	CcSEcCtD
Thalidomide—Muscle spasms—Rivastigmine—Alzheimer's disease	0.000149	0.000679	CcSEcCtD
Thalidomide—Myalgia—Donepezil—Alzheimer's disease	0.000149	0.000677	CcSEcCtD
Thalidomide—Chest pain—Donepezil—Alzheimer's disease	0.000149	0.000677	CcSEcCtD
Thalidomide—Arthralgia—Donepezil—Alzheimer's disease	0.000149	0.000677	CcSEcCtD
Thalidomide—Tremor—Memantine—Alzheimer's disease	0.000149	0.000677	CcSEcCtD
Thalidomide—Anxiety—Donepezil—Alzheimer's disease	0.000148	0.000675	CcSEcCtD
Thalidomide—Ill-defined disorder—Memantine—Alzheimer's disease	0.000147	0.00067	CcSEcCtD
Thalidomide—Discomfort—Donepezil—Alzheimer's disease	0.000147	0.000669	CcSEcCtD
Thalidomide—Anaemia—Memantine—Alzheimer's disease	0.000147	0.000668	CcSEcCtD
Thalidomide—Vision blurred—Rivastigmine—Alzheimer's disease	0.000146	0.000666	CcSEcCtD
Thalidomide—Agitation—Memantine—Alzheimer's disease	0.000146	0.000664	CcSEcCtD
Thalidomide—Dry mouth—Donepezil—Alzheimer's disease	0.000146	0.000662	CcSEcCtD
Thalidomide—Abdominal pain—Galantamine—Alzheimer's disease	0.000145	0.000662	CcSEcCtD
Thalidomide—Body temperature increased—Galantamine—Alzheimer's disease	0.000145	0.000662	CcSEcCtD
Thalidomide—Tremor—Rivastigmine—Alzheimer's disease	0.000145	0.000662	CcSEcCtD
Thalidomide—Ill-defined disorder—Rivastigmine—Alzheimer's disease	0.000144	0.000656	CcSEcCtD
Thalidomide—Confusional state—Donepezil—Alzheimer's disease	0.000144	0.000655	CcSEcCtD
Thalidomide—Anaemia—Rivastigmine—Alzheimer's disease	0.000143	0.000653	CcSEcCtD
Thalidomide—Malaise—Memantine—Alzheimer's disease	0.000143	0.000651	CcSEcCtD
Thalidomide—Agitation—Rivastigmine—Alzheimer's disease	0.000143	0.000649	CcSEcCtD
Thalidomide—Oedema—Donepezil—Alzheimer's disease	0.000143	0.000649	CcSEcCtD
Thalidomide—Vertigo—Memantine—Alzheimer's disease	0.000143	0.000649	CcSEcCtD
Thalidomide—Syncope—Memantine—Alzheimer's disease	0.000142	0.000648	CcSEcCtD
Thalidomide—Leukopenia—Memantine—Alzheimer's disease	0.000142	0.000646	CcSEcCtD
Thalidomide—Infection—Donepezil—Alzheimer's disease	0.000142	0.000645	CcSEcCtD
Thalidomide—Shock—Donepezil—Alzheimer's disease	0.00014	0.000639	CcSEcCtD
Thalidomide—Palpitations—Memantine—Alzheimer's disease	0.00014	0.000638	CcSEcCtD
Thalidomide—Malaise—Rivastigmine—Alzheimer's disease	0.00014	0.000637	CcSEcCtD
Thalidomide—Nervous system disorder—Donepezil—Alzheimer's disease	0.00014	0.000637	CcSEcCtD
Thalidomide—Thrombocytopenia—Donepezil—Alzheimer's disease	0.00014	0.000636	CcSEcCtD
Thalidomide—Vertigo—Rivastigmine—Alzheimer's disease	0.000139	0.000635	CcSEcCtD
Thalidomide—Loss of consciousness—Memantine—Alzheimer's disease	0.000139	0.000635	CcSEcCtD
Thalidomide—Syncope—Rivastigmine—Alzheimer's disease	0.000139	0.000634	CcSEcCtD
Thalidomide—Cough—Memantine—Alzheimer's disease	0.000138	0.00063	CcSEcCtD
Thalidomide—Hyperhidrosis—Donepezil—Alzheimer's disease	0.000138	0.000628	CcSEcCtD
Thalidomide—Convulsion—Memantine—Alzheimer's disease	0.000137	0.000626	CcSEcCtD
Thalidomide—Palpitations—Rivastigmine—Alzheimer's disease	0.000137	0.000624	CcSEcCtD
Thalidomide—Hypertension—Memantine—Alzheimer's disease	0.000137	0.000624	CcSEcCtD
Thalidomide—Loss of consciousness—Rivastigmine—Alzheimer's disease	0.000136	0.000621	CcSEcCtD
Thalidomide—Anorexia—Donepezil—Alzheimer's disease	0.000136	0.000619	CcSEcCtD
Thalidomide—Hypersensitivity—Galantamine—Alzheimer's disease	0.000136	0.000617	CcSEcCtD
Thalidomide—Cough—Rivastigmine—Alzheimer's disease	0.000135	0.000617	CcSEcCtD
Thalidomide—Arthralgia—Memantine—Alzheimer's disease	0.000135	0.000615	CcSEcCtD
Thalidomide—Myalgia—Memantine—Alzheimer's disease	0.000135	0.000615	CcSEcCtD
Thalidomide—Chest pain—Memantine—Alzheimer's disease	0.000135	0.000615	CcSEcCtD
Thalidomide—Anxiety—Memantine—Alzheimer's disease	0.000135	0.000613	CcSEcCtD
Thalidomide—Convulsion—Rivastigmine—Alzheimer's disease	0.000134	0.000612	CcSEcCtD
Thalidomide—Hypertension—Rivastigmine—Alzheimer's disease	0.000134	0.00061	CcSEcCtD
Thalidomide—Discomfort—Memantine—Alzheimer's disease	0.000133	0.000608	CcSEcCtD
Thalidomide—Hypotension—Donepezil—Alzheimer's disease	0.000133	0.000607	CcSEcCtD
Thalidomide—Myalgia—Rivastigmine—Alzheimer's disease	0.000132	0.000602	CcSEcCtD
Thalidomide—Arthralgia—Rivastigmine—Alzheimer's disease	0.000132	0.000602	CcSEcCtD
Thalidomide—Chest pain—Rivastigmine—Alzheimer's disease	0.000132	0.000602	CcSEcCtD
Thalidomide—Dry mouth—Memantine—Alzheimer's disease	0.000132	0.000601	CcSEcCtD
Thalidomide—Asthenia—Galantamine—Alzheimer's disease	0.000132	0.000601	CcSEcCtD
Thalidomide—Anxiety—Rivastigmine—Alzheimer's disease	0.000132	0.000599	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Rivastigmine—Alzheimer's disease	0.000131	0.000597	CcSEcCtD
Thalidomide—Confusional state—Memantine—Alzheimer's disease	0.000131	0.000594	CcSEcCtD
Thalidomide—Discomfort—Rivastigmine—Alzheimer's disease	0.000131	0.000594	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Donepezil—Alzheimer's disease	0.00013	0.000591	CcSEcCtD
Thalidomide—Oedema—Memantine—Alzheimer's disease	0.000129	0.000589	CcSEcCtD
Thalidomide—Dry mouth—Rivastigmine—Alzheimer's disease	0.000129	0.000588	CcSEcCtD
Thalidomide—Insomnia—Donepezil—Alzheimer's disease	0.000129	0.000587	CcSEcCtD
Thalidomide—Infection—Memantine—Alzheimer's disease	0.000129	0.000586	CcSEcCtD
Thalidomide—Paraesthesia—Donepezil—Alzheimer's disease	0.000128	0.000583	CcSEcCtD
Thalidomide—Confusional state—Rivastigmine—Alzheimer's disease	0.000128	0.000581	CcSEcCtD
Thalidomide—Shock—Memantine—Alzheimer's disease	0.000127	0.00058	CcSEcCtD
Thalidomide—Dyspnoea—Donepezil—Alzheimer's disease	0.000127	0.000579	CcSEcCtD
Thalidomide—Nervous system disorder—Memantine—Alzheimer's disease	0.000127	0.000578	CcSEcCtD
Thalidomide—Somnolence—Donepezil—Alzheimer's disease	0.000127	0.000577	CcSEcCtD
Thalidomide—Thrombocytopenia—Memantine—Alzheimer's disease	0.000127	0.000577	CcSEcCtD
Thalidomide—Oedema—Rivastigmine—Alzheimer's disease	0.000127	0.000577	CcSEcCtD
Thalidomide—Tachycardia—Memantine—Alzheimer's disease	0.000126	0.000575	CcSEcCtD
Thalidomide—Diarrhoea—Galantamine—Alzheimer's disease	0.000126	0.000573	CcSEcCtD
Thalidomide—Infection—Rivastigmine—Alzheimer's disease	0.000126	0.000573	CcSEcCtD
Thalidomide—Skin disorder—Memantine—Alzheimer's disease	0.000126	0.000573	CcSEcCtD
Thalidomide—Dyspepsia—Donepezil—Alzheimer's disease	0.000126	0.000571	CcSEcCtD
Thalidomide—Hyperhidrosis—Memantine—Alzheimer's disease	0.000125	0.00057	CcSEcCtD
Thalidomide—Shock—Rivastigmine—Alzheimer's disease	0.000125	0.000567	CcSEcCtD
Thalidomide—Nervous system disorder—Rivastigmine—Alzheimer's disease	0.000124	0.000565	CcSEcCtD
Thalidomide—Thrombocytopenia—Rivastigmine—Alzheimer's disease	0.000124	0.000565	CcSEcCtD
Thalidomide—Decreased appetite—Donepezil—Alzheimer's disease	0.000124	0.000564	CcSEcCtD
Thalidomide—Tachycardia—Rivastigmine—Alzheimer's disease	0.000124	0.000563	CcSEcCtD
Thalidomide—Anorexia—Memantine—Alzheimer's disease	0.000123	0.000562	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Donepezil—Alzheimer's disease	0.000123	0.00056	CcSEcCtD
Thalidomide—Skin disorder—Rivastigmine—Alzheimer's disease	0.000123	0.00056	CcSEcCtD
Thalidomide—Fatigue—Donepezil—Alzheimer's disease	0.000123	0.00056	CcSEcCtD
Thalidomide—Hyperhidrosis—Rivastigmine—Alzheimer's disease	0.000122	0.000557	CcSEcCtD
Thalidomide—Pain—Donepezil—Alzheimer's disease	0.000122	0.000555	CcSEcCtD
Thalidomide—Constipation—Donepezil—Alzheimer's disease	0.000122	0.000555	CcSEcCtD
Thalidomide—Dizziness—Galantamine—Alzheimer's disease	0.000122	0.000554	CcSEcCtD
Thalidomide—Hypotension—Memantine—Alzheimer's disease	0.000121	0.000551	CcSEcCtD
Thalidomide—Anorexia—Rivastigmine—Alzheimer's disease	0.000121	0.00055	CcSEcCtD
Thalidomide—Hypotension—Rivastigmine—Alzheimer's disease	0.000118	0.000539	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Memantine—Alzheimer's disease	0.000118	0.000537	CcSEcCtD
Thalidomide—Feeling abnormal—Donepezil—Alzheimer's disease	0.000118	0.000535	CcSEcCtD
Thalidomide—Insomnia—Memantine—Alzheimer's disease	0.000117	0.000533	CcSEcCtD
Thalidomide—Vomiting—Galantamine—Alzheimer's disease	0.000117	0.000533	CcSEcCtD
Thalidomide—Gastrointestinal pain—Donepezil—Alzheimer's disease	0.000117	0.000531	CcSEcCtD
Thalidomide—Paraesthesia—Memantine—Alzheimer's disease	0.000116	0.000529	CcSEcCtD
Thalidomide—Rash—Galantamine—Alzheimer's disease	0.000116	0.000528	CcSEcCtD
Thalidomide—Dermatitis—Galantamine—Alzheimer's disease	0.000116	0.000528	CcSEcCtD
Thalidomide—Dyspnoea—Memantine—Alzheimer's disease	0.000115	0.000526	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Rivastigmine—Alzheimer's disease	0.000115	0.000525	CcSEcCtD
Thalidomide—Headache—Galantamine—Alzheimer's disease	0.000115	0.000525	CcSEcCtD
Thalidomide—Somnolence—Memantine—Alzheimer's disease	0.000115	0.000524	CcSEcCtD
Thalidomide—Insomnia—Rivastigmine—Alzheimer's disease	0.000115	0.000522	CcSEcCtD
Thalidomide—Dyspepsia—Memantine—Alzheimer's disease	0.000114	0.000519	CcSEcCtD
Thalidomide—Paraesthesia—Rivastigmine—Alzheimer's disease	0.000114	0.000518	CcSEcCtD
Thalidomide—Urticaria—Donepezil—Alzheimer's disease	0.000113	0.000516	CcSEcCtD
Thalidomide—Dyspnoea—Rivastigmine—Alzheimer's disease	0.000113	0.000514	CcSEcCtD
Thalidomide—Abdominal pain—Donepezil—Alzheimer's disease	0.000113	0.000513	CcSEcCtD
Thalidomide—Body temperature increased—Donepezil—Alzheimer's disease	0.000113	0.000513	CcSEcCtD
Thalidomide—Somnolence—Rivastigmine—Alzheimer's disease	0.000113	0.000513	CcSEcCtD
Thalidomide—Decreased appetite—Memantine—Alzheimer's disease	0.000113	0.000512	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Memantine—Alzheimer's disease	0.000112	0.000509	CcSEcCtD
Thalidomide—Fatigue—Memantine—Alzheimer's disease	0.000112	0.000508	CcSEcCtD
Thalidomide—Dyspepsia—Rivastigmine—Alzheimer's disease	0.000112	0.000508	CcSEcCtD
Thalidomide—Pain—Memantine—Alzheimer's disease	0.000111	0.000504	CcSEcCtD
Thalidomide—Constipation—Memantine—Alzheimer's disease	0.000111	0.000504	CcSEcCtD
Thalidomide—Decreased appetite—Rivastigmine—Alzheimer's disease	0.00011	0.000501	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Rivastigmine—Alzheimer's disease	0.000109	0.000498	CcSEcCtD
Thalidomide—Nausea—Galantamine—Alzheimer's disease	0.000109	0.000498	CcSEcCtD
Thalidomide—Fatigue—Rivastigmine—Alzheimer's disease	0.000109	0.000497	CcSEcCtD
Thalidomide—Pain—Rivastigmine—Alzheimer's disease	0.000108	0.000493	CcSEcCtD
Thalidomide—Constipation—Rivastigmine—Alzheimer's disease	0.000108	0.000493	CcSEcCtD
Thalidomide—Feeling abnormal—Memantine—Alzheimer's disease	0.000107	0.000486	CcSEcCtD
Thalidomide—Gastrointestinal pain—Memantine—Alzheimer's disease	0.000106	0.000482	CcSEcCtD
Thalidomide—Hypersensitivity—Donepezil—Alzheimer's disease	0.000105	0.000478	CcSEcCtD
Thalidomide—Feeling abnormal—Rivastigmine—Alzheimer's disease	0.000104	0.000475	CcSEcCtD
Thalidomide—Gastrointestinal pain—Rivastigmine—Alzheimer's disease	0.000104	0.000472	CcSEcCtD
Thalidomide—Urticaria—Memantine—Alzheimer's disease	0.000103	0.000468	CcSEcCtD
Thalidomide—Abdominal pain—Memantine—Alzheimer's disease	0.000102	0.000466	CcSEcCtD
Thalidomide—Body temperature increased—Memantine—Alzheimer's disease	0.000102	0.000466	CcSEcCtD
Thalidomide—Asthenia—Donepezil—Alzheimer's disease	0.000102	0.000466	CcSEcCtD
Thalidomide—Pruritus—Donepezil—Alzheimer's disease	0.000101	0.000459	CcSEcCtD
Thalidomide—Urticaria—Rivastigmine—Alzheimer's disease	0.000101	0.000458	CcSEcCtD
Thalidomide—Abdominal pain—Rivastigmine—Alzheimer's disease	0.0001	0.000456	CcSEcCtD
Thalidomide—Body temperature increased—Rivastigmine—Alzheimer's disease	0.0001	0.000456	CcSEcCtD
Thalidomide—Diarrhoea—Donepezil—Alzheimer's disease	9.76e-05	0.000444	CcSEcCtD
Thalidomide—Hypersensitivity—Memantine—Alzheimer's disease	9.54e-05	0.000434	CcSEcCtD
Thalidomide—Dizziness—Donepezil—Alzheimer's disease	9.43e-05	0.000429	CcSEcCtD
Thalidomide—Hypersensitivity—Rivastigmine—Alzheimer's disease	9.33e-05	0.000425	CcSEcCtD
Thalidomide—Asthenia—Memantine—Alzheimer's disease	9.29e-05	0.000423	CcSEcCtD
Thalidomide—Pruritus—Memantine—Alzheimer's disease	9.16e-05	0.000417	CcSEcCtD
Thalidomide—Asthenia—Rivastigmine—Alzheimer's disease	9.09e-05	0.000414	CcSEcCtD
Thalidomide—Vomiting—Donepezil—Alzheimer's disease	9.07e-05	0.000413	CcSEcCtD
Thalidomide—Rash—Donepezil—Alzheimer's disease	8.99e-05	0.000409	CcSEcCtD
Thalidomide—Dermatitis—Donepezil—Alzheimer's disease	8.98e-05	0.000409	CcSEcCtD
Thalidomide—Pruritus—Rivastigmine—Alzheimer's disease	8.96e-05	0.000408	CcSEcCtD
Thalidomide—Headache—Donepezil—Alzheimer's disease	8.93e-05	0.000407	CcSEcCtD
Thalidomide—Diarrhoea—Memantine—Alzheimer's disease	8.86e-05	0.000403	CcSEcCtD
Thalidomide—Diarrhoea—Rivastigmine—Alzheimer's disease	8.67e-05	0.000395	CcSEcCtD
Thalidomide—Dizziness—Memantine—Alzheimer's disease	8.56e-05	0.00039	CcSEcCtD
Thalidomide—Nausea—Donepezil—Alzheimer's disease	8.47e-05	0.000386	CcSEcCtD
Thalidomide—Dizziness—Rivastigmine—Alzheimer's disease	8.38e-05	0.000381	CcSEcCtD
Thalidomide—Vomiting—Memantine—Alzheimer's disease	8.23e-05	0.000375	CcSEcCtD
Thalidomide—Rash—Memantine—Alzheimer's disease	8.17e-05	0.000372	CcSEcCtD
Thalidomide—Dermatitis—Memantine—Alzheimer's disease	8.16e-05	0.000371	CcSEcCtD
Thalidomide—Headache—Memantine—Alzheimer's disease	8.11e-05	0.000369	CcSEcCtD
Thalidomide—Vomiting—Rivastigmine—Alzheimer's disease	8.05e-05	0.000367	CcSEcCtD
Thalidomide—Rash—Rivastigmine—Alzheimer's disease	7.99e-05	0.000364	CcSEcCtD
Thalidomide—Dermatitis—Rivastigmine—Alzheimer's disease	7.98e-05	0.000363	CcSEcCtD
Thalidomide—Headache—Rivastigmine—Alzheimer's disease	7.94e-05	0.000361	CcSEcCtD
Thalidomide—Nausea—Memantine—Alzheimer's disease	7.69e-05	0.00035	CcSEcCtD
Thalidomide—Nausea—Rivastigmine—Alzheimer's disease	7.52e-05	0.000343	CcSEcCtD
Thalidomide—NFKB1—Signaling Pathways—APOE—Alzheimer's disease	6.7e-06	4.49e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—LEP—Alzheimer's disease	6.7e-06	4.49e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—LPL—Alzheimer's disease	6.7e-06	4.48e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—INPP5D—Alzheimer's disease	6.69e-06	4.48e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—IL6—Alzheimer's disease	6.64e-06	4.45e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CAV1—Alzheimer's disease	6.64e-06	4.44e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CYP2D6—Alzheimer's disease	6.62e-06	4.43e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL1B—Alzheimer's disease	6.61e-06	4.42e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	6.56e-06	4.39e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MAOB—Alzheimer's disease	6.47e-06	4.33e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—ADAM10—Alzheimer's disease	6.45e-06	4.31e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—ESR1—Alzheimer's disease	6.4e-06	4.28e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ACHE—Alzheimer's disease	6.4e-06	4.28e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CALM1—Alzheimer's disease	6.38e-06	4.27e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—LEP—Alzheimer's disease	6.36e-06	4.26e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—APOE—Alzheimer's disease	6.36e-06	4.26e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ENO1—Alzheimer's disease	6.36e-06	4.25e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS1—Alzheimer's disease	6.36e-06	4.25e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ENO1—Alzheimer's disease	6.34e-06	4.25e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS1—Alzheimer's disease	6.34e-06	4.25e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—INPP5D—Alzheimer's disease	6.32e-06	4.23e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—F2—Alzheimer's disease	6.32e-06	4.23e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—IL6—Alzheimer's disease	6.3e-06	4.22e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CAV1—Alzheimer's disease	6.3e-06	4.22e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARGC1A—Alzheimer's disease	6.29e-06	4.21e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—BCHE—Alzheimer's disease	6.28e-06	4.2e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL1B—Alzheimer's disease	6.27e-06	4.2e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARGC1A—Alzheimer's disease	6.23e-06	4.17e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CYP2D6—Alzheimer's disease	6.23e-06	4.17e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—GAPDH—Alzheimer's disease	6.23e-06	4.17e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—Alzheimer's disease	6.22e-06	4.16e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CYP2D6—Alzheimer's disease	6.22e-06	4.16e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—HMOX1—Alzheimer's disease	6.21e-06	4.15e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOTCH1—Alzheimer's disease	6.19e-06	4.14e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	6.16e-06	4.12e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CHAT—Alzheimer's disease	6.16e-06	4.12e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPI1—Alzheimer's disease	6.16e-06	4.12e-05	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—Alzheimer's disease	6.13e-06	4.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	6.1e-06	4.08e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—ESR1—Alzheimer's disease	6.07e-06	4.06e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—MAPK8—Alzheimer's disease	6.06e-06	4.06e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—A2M—Alzheimer's disease	6.02e-06	4.03e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—F2—Alzheimer's disease	6e-06	4.01e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ENO1—Alzheimer's disease	5.99e-06	4.01e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS1—Alzheimer's disease	5.99e-06	4.01e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PLCB1—Alzheimer's disease	5.92e-06	3.96e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—BCHE—Alzheimer's disease	5.91e-06	3.95e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MAOB—Alzheimer's disease	5.9e-06	3.95e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—BCHE—Alzheimer's disease	5.9e-06	3.95e-05	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—Alzheimer's disease	5.89e-06	3.94e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CYP2D6—Alzheimer's disease	5.88e-06	3.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOTCH1—Alzheimer's disease	5.87e-06	3.93e-05	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—Alzheimer's disease	5.82e-06	3.89e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—GSK3B—Alzheimer's disease	5.8e-06	3.88e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CREB1—Alzheimer's disease	5.76e-06	3.85e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—MAPK8—Alzheimer's disease	5.75e-06	3.85e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—ABCA1—Alzheimer's disease	5.74e-06	3.84e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—IL6—Alzheimer's disease	5.73e-06	3.84e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—INS—Alzheimer's disease	5.73e-06	3.83e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—LPL—Alzheimer's disease	5.73e-06	3.83e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—GAPDH—Alzheimer's disease	5.68e-06	3.8e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—LPL—Alzheimer's disease	5.68e-06	3.8e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCL2—Alzheimer's disease	5.63e-06	3.77e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	5.62e-06	3.76e-05	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—Alzheimer's disease	5.59e-06	3.74e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PLCB1—Alzheimer's disease	5.58e-06	3.73e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—BCHE—Alzheimer's disease	5.57e-06	3.73e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PLCB1—Alzheimer's disease	5.57e-06	3.72e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	5.56e-06	3.72e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IGF1—Alzheimer's disease	5.54e-06	3.71e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—GSK3B—Alzheimer's disease	5.51e-06	3.69e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—A2M—Alzheimer's disease	5.49e-06	3.67e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CREB1—Alzheimer's disease	5.46e-06	3.66e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—INS—Alzheimer's disease	5.43e-06	3.64e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—ABCA1—Alzheimer's disease	5.41e-06	3.62e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—ABCA1—Alzheimer's disease	5.39e-06	3.61e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—LPL—Alzheimer's disease	5.38e-06	3.6e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	5.37e-06	3.59e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCL2—Alzheimer's disease	5.35e-06	3.58e-05	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—Alzheimer's disease	5.29e-06	3.54e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CHAT—Alzheimer's disease	5.26e-06	3.52e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPI1—Alzheimer's disease	5.26e-06	3.52e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PLCB1—Alzheimer's disease	5.26e-06	3.52e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IGF1—Alzheimer's disease	5.26e-06	3.52e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ACHE—Alzheimer's disease	5.23e-06	3.5e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PRKCG—Alzheimer's disease	5.23e-06	3.5e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—INPP5D—Alzheimer's disease	5.17e-06	3.46e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	5.16e-06	3.45e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—MTHFR—Alzheimer's disease	5.11e-06	3.42e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—ABCA1—Alzheimer's disease	5.1e-06	3.41e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MAOB—Alzheimer's disease	5.04e-06	3.37e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NOS3—Alzheimer's disease	5.02e-06	3.36e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CCR5—Alzheimer's disease	4.96e-06	3.32e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARGC1A—Alzheimer's disease	4.95e-06	3.31e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—HMOX1—Alzheimer's disease	4.93e-06	3.3e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ENO1—Alzheimer's disease	4.91e-06	3.28e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS1—Alzheimer's disease	4.91e-06	3.28e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	4.89e-06	3.27e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—GAPDH—Alzheimer's disease	4.85e-06	3.25e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MTHFR—Alzheimer's disease	4.84e-06	3.24e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CYP2D6—Alzheimer's disease	4.81e-06	3.22e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—Alzheimer's disease	4.8e-06	3.21e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CALM1—Alzheimer's disease	4.77e-06	3.2e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ACHE—Alzheimer's disease	4.77e-06	3.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NOS3—Alzheimer's disease	4.76e-06	3.19e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—APOE—Alzheimer's disease	4.76e-06	3.18e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—Alzheimer's disease	4.76e-06	3.18e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—INPP5D—Alzheimer's disease	4.72e-06	3.16e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—CAV1—Alzheimer's disease	4.71e-06	3.15e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—A2M—Alzheimer's disease	4.69e-06	3.14e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARGC1A—Alzheimer's disease	4.66e-06	3.12e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARGC1A—Alzheimer's disease	4.65e-06	3.11e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HMOX1—Alzheimer's disease	4.64e-06	3.1e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HMOX1—Alzheimer's disease	4.63e-06	3.1e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—BCHE—Alzheimer's disease	4.56e-06	3.05e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CALM1—Alzheimer's disease	4.53e-06	3.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—APOE—Alzheimer's disease	4.51e-06	3.02e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—LPL—Alzheimer's disease	4.51e-06	3.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TGFB1—Alzheimer's disease	4.5e-06	3.01e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ENO1—Alzheimer's disease	4.47e-06	2.99e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS1—Alzheimer's disease	4.47e-06	2.99e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CAV1—Alzheimer's disease	4.47e-06	2.99e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARGC1A—Alzheimer's disease	4.39e-06	2.94e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CYP2D6—Alzheimer's disease	4.39e-06	2.93e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HMOX1—Alzheimer's disease	4.37e-06	2.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PLCB1—Alzheimer's disease	4.3e-06	2.88e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CASP3—Alzheimer's disease	4.26e-06	2.85e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—LPL—Alzheimer's disease	4.24e-06	2.84e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—LPL—Alzheimer's disease	4.23e-06	2.83e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	4.22e-06	2.82e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS2—Alzheimer's disease	4.2e-06	2.81e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—Alzheimer's disease	4.18e-06	2.8e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—ABCA1—Alzheimer's disease	4.17e-06	2.79e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOTCH1—Alzheimer's disease	4.16e-06	2.79e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—BCHE—Alzheimer's disease	4.16e-06	2.78e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—Alzheimer's disease	4.14e-06	2.77e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ACHE—Alzheimer's disease	4.08e-06	2.73e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—INS—Alzheimer's disease	4.06e-06	2.72e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—MTHFR—Alzheimer's disease	4.06e-06	2.71e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CASP3—Alzheimer's disease	4.05e-06	2.71e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—INPP5D—Alzheimer's disease	4.03e-06	2.7e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—LPL—Alzheimer's disease	4e-06	2.68e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PLCB1—Alzheimer's disease	3.92e-06	2.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MAPK8—Alzheimer's disease	3.92e-06	2.62e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—GSK3B—Alzheimer's disease	3.91e-06	2.61e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CREB1—Alzheimer's disease	3.87e-06	2.59e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IL6—Alzheimer's disease	3.87e-06	2.59e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—INS—Alzheimer's disease	3.85e-06	2.58e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	3.85e-06	2.58e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ENO1—Alzheimer's disease	3.82e-06	2.56e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS1—Alzheimer's disease	3.82e-06	2.56e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—MTHFR—Alzheimer's disease	3.82e-06	2.56e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—MTHFR—Alzheimer's disease	3.81e-06	2.55e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—ABCA1—Alzheimer's disease	3.8e-06	2.54e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CALM1—Alzheimer's disease	3.79e-06	2.54e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—APOE—Alzheimer's disease	3.78e-06	2.53e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CYP2D6—Alzheimer's disease	3.75e-06	2.51e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—CAV1—Alzheimer's disease	3.74e-06	2.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MAPK8—Alzheimer's disease	3.72e-06	2.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—IL6—Alzheimer's disease	3.67e-06	2.46e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—VEGFA—Alzheimer's disease	3.62e-06	2.42e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—MTHFR—Alzheimer's disease	3.6e-06	2.41e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARGC1A—Alzheimer's disease	3.59e-06	2.41e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HMOX1—Alzheimer's disease	3.58e-06	2.39e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—Alzheimer's disease	3.57e-06	2.39e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CALM1—Alzheimer's disease	3.57e-06	2.39e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—NOS3—Alzheimer's disease	3.56e-06	2.39e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CALM1—Alzheimer's disease	3.56e-06	2.38e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—APOE—Alzheimer's disease	3.56e-06	2.38e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—BCHE—Alzheimer's disease	3.55e-06	2.38e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—APOE—Alzheimer's disease	3.55e-06	2.37e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—CAV1—Alzheimer's disease	3.52e-06	2.36e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—CAV1—Alzheimer's disease	3.52e-06	2.35e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—VEGFA—Alzheimer's disease	3.43e-06	2.3e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—IL6—Alzheimer's disease	3.39e-06	2.27e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—Alzheimer's disease	3.39e-06	2.27e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NOS3—Alzheimer's disease	3.38e-06	2.26e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CALM1—Alzheimer's disease	3.36e-06	2.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PLCB1—Alzheimer's disease	3.35e-06	2.24e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—APOE—Alzheimer's disease	3.35e-06	2.24e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—CAV1—Alzheimer's disease	3.32e-06	2.22e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TGFB1—Alzheimer's disease	3.32e-06	2.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—Alzheimer's disease	3.29e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—Alzheimer's disease	3.29e-06	2.2e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARGC1A—Alzheimer's disease	3.28e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—LPL—Alzheimer's disease	3.27e-06	2.19e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HMOX1—Alzheimer's disease	3.26e-06	2.18e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—Alzheimer's disease	3.26e-06	2.18e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—ABCA1—Alzheimer's disease	3.25e-06	2.17e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—INS—Alzheimer's disease	3.23e-06	2.16e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TGFB1—Alzheimer's disease	3.15e-06	2.11e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—Alzheimer's disease	3.13e-06	2.09e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—Alzheimer's disease	3.1e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—Alzheimer's disease	3.09e-06	2.07e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—INS—Alzheimer's disease	3.04e-06	2.03e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—INS—Alzheimer's disease	3.03e-06	2.03e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—LPL—Alzheimer's disease	2.98e-06	2e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—MTHFR—Alzheimer's disease	2.95e-06	1.97e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—Alzheimer's disease	2.92e-06	1.95e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—INS—Alzheimer's disease	2.86e-06	1.92e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—NOS3—Alzheimer's disease	2.83e-06	1.89e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARGC1A—Alzheimer's disease	2.8e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HMOX1—Alzheimer's disease	2.79e-06	1.87e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CALM1—Alzheimer's disease	2.75e-06	1.84e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—APOE—Alzheimer's disease	2.74e-06	1.84e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—Alzheimer's disease	2.73e-06	1.83e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CAV1—Alzheimer's disease	2.72e-06	1.82e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—MTHFR—Alzheimer's disease	2.69e-06	1.8e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—NOS3—Alzheimer's disease	2.66e-06	1.78e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—NOS3—Alzheimer's disease	2.66e-06	1.78e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—Alzheimer's disease	2.59e-06	1.74e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—LPL—Alzheimer's disease	2.55e-06	1.71e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—NOS3—Alzheimer's disease	2.51e-06	1.68e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CALM1—Alzheimer's disease	2.51e-06	1.68e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—IL6—Alzheimer's disease	2.5e-06	1.67e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—APOE—Alzheimer's disease	2.5e-06	1.67e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CAV1—Alzheimer's disease	2.48e-06	1.66e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—Alzheimer's disease	2.44e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—Alzheimer's disease	2.43e-06	1.63e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—Alzheimer's disease	2.39e-06	1.6e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—IL6—Alzheimer's disease	2.37e-06	1.59e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—INS—Alzheimer's disease	2.34e-06	1.57e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—Alzheimer's disease	2.31e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—Alzheimer's disease	2.3e-06	1.54e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MTHFR—Alzheimer's disease	2.3e-06	1.54e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TGFB1—Alzheimer's disease	2.23e-06	1.5e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—Alzheimer's disease	2.19e-06	1.47e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—Alzheimer's disease	2.18e-06	1.46e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CALM1—Alzheimer's disease	2.15e-06	1.44e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—APOE—Alzheimer's disease	2.14e-06	1.43e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—INS—Alzheimer's disease	2.14e-06	1.43e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CAV1—Alzheimer's disease	2.12e-06	1.42e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NOS3—Alzheimer's disease	2.06e-06	1.38e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—Alzheimer's disease	1.88e-06	1.26e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NOS3—Alzheimer's disease	1.87e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—Alzheimer's disease	1.86e-06	1.25e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—INS—Alzheimer's disease	1.83e-06	1.22e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—Alzheimer's disease	1.71e-06	1.15e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—IL6—Alzheimer's disease	1.68e-06	1.13e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—Alzheimer's disease	1.64e-06	1.1e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NOS3—Alzheimer's disease	1.6e-06	1.07e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—Alzheimer's disease	1.55e-06	1.04e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—Alzheimer's disease	1.46e-06	9.8e-06	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—Alzheimer's disease	1.3e-06	8.7e-06	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—Alzheimer's disease	1.22e-06	8.19e-06	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—Alzheimer's disease	1.22e-06	8.18e-06	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—Alzheimer's disease	1.15e-06	7.73e-06	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—Alzheimer's disease	9.45e-07	6.32e-06	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—Alzheimer's disease	8.61e-07	5.76e-06	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—Alzheimer's disease	7.36e-07	4.93e-06	CbGpPWpGaD
